Characterization of NPM1 and FLT3-ITD Mutations in Iraqi Patients with AML
نویسندگان
چکیده
Acute myeloid leukemia is a malignant disease results from mutation in multipotent haemopoietic stemcell. The study aimed to investigate NPM1 and FLT3-ITD mutations Iraqi patients with AML correlateresults other clinical laboratory findings. Fifty-eight patients, admitted Baghdad TeachingHospital October 2019 till March 2020 addition 25 normal controls, were included the study.A detailed history, investigations including collected fromand analyzed. was detected 17.24% of 10.34%. Most thepatients are presented pallor. had higher blast cell count (74%) while NPM1mutation WBCs count.Conclusion: common middle age group, significantly higherWBCs have percentage compared nonmutated patients.
منابع مشابه
Frequency of FLT3 ITD and FLT3 TKD Mutations in Multiple Myeloma Patients (A Case Control Study)
Background and Aims: Multiple myeloma is a malignant proliferation of plasma cells derived from a single clone. The tumor, its products and the host response lead to organ damages. Some factors that are responsible in its pathogenesis are recognized. As FMS like Tyrosine Kinase 3 receptor (FLT3) mutation has been proved as a determining factor in leukemic patients the goal of this study was to ...
متن کاملAML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
Activating mutations of Flt3 are found in approximately one third of patients with acute myeloid leukemia (AML) and are an attractive drug target. Two classes of Flt3 mutations occur: internal tandem duplications (ITDs) in the juxtamembrane and point mutations in the tyrosine kinase domain (TKD). We and others have shown that Flt3-ITD induced aberrant signaling including strong activation of si...
متن کاملMutations in AML with a normal karyotype: NPM1 and FLT3-ITD, ready to use as a key prognosticator?
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Two well defined mutations, including the NPM1 and CCAAT/enhancer-binding protein-alpha (CEBPA) genes, are generally accepted as a better prognosis in AML [1]. NPM1, one of frequent mutations in AML, have been described in association with several clinical f...
متن کاملNPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
Mutations in the NPM1 gene represent the most frequent genetic alterations in patients with acute myeloid leukemia (AML) and are associated with a favorable outcome. In 690 normal karyotype (NK) AML patients the complete remission rates (CRs) and the percentage of patients with adequate in vivo blast cell reduction 1 week after the end of the first induction cycle were significantly higher in N...
متن کاملPediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Pediatric acute myelogenous leukemia (AML) has a poor prognosis, and novel therapies are needed. The FLT3 tyrosine kinase represents a promising target in pediatric AML. FLT3 is constitutively activated either by an internal tandem duplication (ITD) or by a point mutation (PM) in 17% to 24% of pediatric AML cases. Autocrine stimulation of wild-type (WT) FLT3 by coexpressed FLT3 ligand (FL) occu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medico-Legal Update
سال: 2021
ISSN: ['0971-720X', '0974-1283']
DOI: https://doi.org/10.37506/mlu.v21i2.2659